Coronavirus Disease 2019 (COVID-19) vaccine is under clinical development by HDT Bio and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Coronavirus Disease 2019 (COVID-19) vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Coronavirus Disease 2019 (COVID-19) vaccine overview
Coronavirus Disease 2019 (Gemcovac) is an in-vitro transcribed self-amplifying mRNA encoding for the S-protein of SARS-CoV-2 vaccine. It is formulated as lyophilized powder for solution for intramuscular route of administration. Gemcovac is indicated for the active immunization of individuals above 18 years old for the prevention of COVID-19.
HGC-019 is under development for the prevention of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is a mRNA vaccine delivered through lipid inorganic nanoparticle (LION) to express spike protein of coronavirus. It is administered by intramuscular route. The therapeutic drug candidate is a self-replicating nanoparticle carrier replicon RNA carrier (repRNA) vaccine. It is being developed by AMPLIFY platform.
HDT Bio overview
HDT Bio is a clinical-stage biopharmaceutical company that discovers and develops treatments for cancers and infectious diseases. The company pipeline products include HDT-301, HDT-321, HDT-331, HDT-201, HDT-501, HDT-511 and HDT-521. HDT Bio product indications include COVID-19, Crimean-Congo Haemorrhagic Fever (CCHF), Nipah, Respiratory Infection, Breast Cancer, Pancreatic Cancer and Prostate Cancer. The company also utilizes LION platform, an RNA (ribonucleic acid) delivery technology that stabilizes, protects, and transports RNA during formulation and administration to enable immune stimulants and disease antigens reach target cells for expression. HDT Bio is headquartered in Seattle, Washington, the US.
For a complete picture of Coronavirus Disease 2019 (COVID-19) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
